drugset
Drugs / BIIB800
last change Oct 2024 re-read 3 minutes ago

BIIB800

Investigated by
Biogen

Trials 1

today NCT06262477 · Ph 1
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06262477 Jan → Sep 2024 — Biogen Completed No outcome recorded

Press releases naming this drug 2 releases

DateIssuerRelease
2022-12-09 Biogen FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab) biogen.com ↗
2022-09-30 Biogen Biogen Announced EMA Filing Acceptance of BIIB800, A Biosimilar Candidate Referencing RoACTEMRA® (tocilizumab) biogen.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as BIIB800 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06262477 ↗
Route Subcutaneous “administered SC in the outer area of the upper arm” NCT06262477 ↗